Soluble PD-L1 as an early marker of progressive disease on nivolumab

Soluble PD-L1 as an early marker of progressive disease on nivolumab

Background Soluble PD-L1 (sPD-L1) has been associated with worse prognosis in numerous solid tumors. We determined sPD-L1 levels before and during nivolumab treatment in two prospective clinical trials of metastatic clear cell renal cell carcinoma (RCC) and melanoma patients, and investigated its re...

Full description

Bibliographic Details
Main Authors: David F McDermott, Gordon J Freeman, Toni K Choueiri, Petra Ross-MacDonald, F Stephen Hodi, Megan Wind-Rotolo, Long Yuan, Kathleen M Mahoney, Linan Song, Eliseo Veras
Format: Article
Language:English
Published: BMJ Publishing Group 2022-02-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/10/2/e003527.full

Internet

https://jitc.bmj.com/content/10/2/e003527.full

Similar Items